IFBC acted as exclusive financial advisor to Takeda
In late March 2021, the Swiss affiliate of the global pharmaceutical company Takeda successfully divested part of its home delivery business to a Swiss partner who will provide these services on behalf of Takeda in the future. The divestment also included an existing Pharmacy serving part of a German-speaking region of Switzerland.
IFBC acted as exclusive M&A advisor to Takeda during the entire transaction process. IFBC supported Takeda in preparing and structuring the transaction, conducted a meaningful buyer approach, coordinated the due diligence, and supported the contract negotiations.
Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda focuses on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Over 50’000 Takeda employees are committed to improving quality of life for patients and to working with partners in health care in more than 70 countries.